Inactive

The U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER) is conducting market research to support the Hursh Laboratory in the Division of Cellular and Gene Ther... The U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER) is conducting market research to support the Hursh Laboratory in the Division of Cellular and Gene Therapies (DCGT) in the Office of Tissue, and Advanced Therapies (OTAT). The Laboratory requires a brand name or equal Bioprofile Flex2 System to support new research programs on the effects of stem cell culture conditions on genomic and epigenetic stability, mitochondrial function, and gene expression.